【摘要】 目的探讨对癌症合并肝转移患者予以双重介入治疗的临床效果与安全性。方法择取2014年1月~2017年1月于我院接受治疗的原发性肺癌合并肝转移患者240例,将其通过随机摸球法分为试验组与对照组,各120例。对照组通过静脉给药的方式进行化疗,试验组则进行双重介入治疗,对比两组患者的治疗效果及不良反应情况。结果试验组的肝、肺肿瘤体积改善率以及6个月的生存率分别为62.50%、56.67%、65.83%,显著高于对照组的37.50%、30.83%、37.50%;而症状指数以及VAS评分显著低于对照组,差异具有统计学意义(P<0.05)。试验组的肝功能异常率、肾功能异常率、WBC异常率、并发症发生率分别为62.50%、15.83%、46.67%、11.67%,均显著低于对照组的85.83%、37.50%、66.67%、29.17%,差异具有统计学意义(P<0.05)。结论对癌症合并肝转移患者予以双重介入治疗能够改善预后效果,同时治疗的安全性较高,应当将这一治疗方法进行推广。更多还原

【Abstract】 Objective To investigate the clinical effectiveness and safety of double intervention therapy in patients with cancer combined with hepatic metastasis.Methods 240 patients with primary lung cancer combined with hepatic metastasis in our hospital from January,2014 to January,2017 were divided into study group and control group with120 patients in each using random feeling ball method.Patients in control group were treated with chemotherapy by intravenous administration while patients in study group were treated with double intervention therapy.Effectiveness of treatment and adverse effects in two groups were compared.Results The improvement rates of lung and live tumor volumes and 6-month survival rate in study group were 62.50%,56.67% and 65.83% respectively,which were significantly higher than those in control group(37.50%,30.83% and 37.50%)(P<0.05).Symptom index and score of VAS in study group were significantly lower than those in control group(P<0.05).The incidence of hepatic dysfunction,renal dysfunction,WBC abnormality and complications was 62.50%,15.83%,46.67% and 11.67% respectively,which was significantly lower than that in control group(85.83%,37.50%,66.67% and 29.17%)(P<0.05).Conclusion Double intervention therapy could improve the prognosis of patients with cancer combined with hepatic metastasis and was with high safety.It was worth promotion.更多还原